Department of Health Outcomes and Behavior, Moffitt Cancer Center, Tampa, Florida.
Department of Family and Community Medicine, Penn State College of Medicine, Hershey, Pennsylvania.
Cancer Epidemiol Biomarkers Prev. 2023 Jun 1;32(6):768-775. doi: 10.1158/1055-9965.EPI-22-1157.
Prostate cancer affects African American men disproportionately compared with men of other racial/ethnic groups. To identify biological bases for this health disparity, we sought to create a state-wide biobank of African American prostate cancer survivors in Florida.
African American men diagnosed with prostate cancer between 2013 and 2017 and living in Florida at diagnosis were identified through the State of Florida's cancer registry. Individuals were approached via mail and telephone, assessed for eligibility, and asked for informed consent. χ2 and t tests were conducted to identify differences between eligible and reachable individuals (i.e., had valid contact information) versus consented participants.
Of the 5,960 eligible and reachable individuals, 3,904 were eligible and contacted at least once, and 578 consented [overall consent rate = 10% (578/5,960); adjusted consent rate = 15% (578/3,904)]. Statistically significant (Ps < 0.05) but small differences in demographic and clinical variables were observed. Consented participants were less likely to be older than 64 (35% vs. 41%) and less likely to have received radiotherapy (36% vs. 41%) and hormone therapy (16% vs. 21%), but more likely to have regional prostate cancer (13% vs. 11%) and have undergone surgery (44% vs. 39%). Consented participants did not differ from reachable individuals on other demographic and clinical factors (Ps > 0.05).
Recruiting African American prostate cancer survivors to biobanking research through a cancer registry is feasible. However, the consent rate was low, and existing challenges limit consent and participation.
Strategies for overcoming barriers to informed consent and increasing participation in biospecimen research are needed to address cancer disparities.
与其他种族/族裔群体的男性相比，前列腺癌在非裔美国男性中发病率不成比例。为了确定这种健康差异的生物学基础，我们试图在佛罗里达州建立一个非裔美国前列腺癌幸存者的全州生物库。
通过佛罗里达州的癌症登记处，确定了 2013 年至 2017 年间被诊断患有前列腺癌且在诊断时居住在佛罗里达州的非裔美国男性。通过邮件和电话与个人联系，评估其资格，并征求知情同意。χ2 和 t 检验用于确定符合条件和可联系的个体（即具有有效联系方式）与同意参加的个体之间的差异。
在 5960 名符合条件且可联系的个体中，有 3904 名符合条件并至少联系过一次，有 578 名同意（总体同意率为 10%（578/5960）；调整后的同意率为 15%（578/3904））。在人口统计学和临床变量方面观察到了统计学上显著（P < 0.05）但很小的差异。同意参加的个体不太可能年龄超过 64 岁（35%比 41%），不太可能接受放射治疗（36%比 41%）和激素治疗（16%比 21%），但更可能患有局部前列腺癌（13%比 11%）并接受过手术（44%比 39%）。同意参加的个体在其他人口统计学和临床因素上与可联系的个体没有差异（P > 0.05）。
通过癌症登记处招募非裔美国前列腺癌幸存者参与生物库研究是可行的。然而，同意率很低，现有的挑战限制了同意和参与。
需要制定克服知情同意障碍和增加生物样本研究参与度的策略，以解决癌症差异问题。
